

CURRICULUM VITAE

Emma Cacciola

Associate Professor of Hematology

Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia"
University of Catania

Education/Training

1982 M.D. Degree, Medical School, University of Catania

1985 Postgraduate Degree in Hematology, Institute of Hematology, University of Catania

1992 Postgraduate Degree in Oncology, Institute of General Pathology, University of Catania

1996 Assistant Professor of Hematology, Hematology Unit, University of Catania

1998-act Professor of Hematology, Masterly Degree Course in Medicine, School of Medicine, University of Catania

1998-act Professor of Hematology, Specialization School of Hematology, School of Medicine, University of Catania

2001-2020 Professor of Hematology, I Level Degree Course in Biomedical Laboratory Techniques, School of Medicine, University of Catania

2004-2011 Professor of Hematology, Specialistic Degree Course in Health Biology, School of Mathematical, Physical and Natural Sciences, School of Medicine, University of Catania

2005-2022 Aggregate Professor of Hematology, School of Medicine, University of Catania

2000-2008 Professor of Hematology, PhD "Immunogenetic, Immunological and Technological Experimentations on application of the xenotransplantations and of the organ withdrawals for human transplantation" "XVI", XXII, XXIII cycle, University of Catania.

2004-2011 Professor of Hematology PhD "Medical Embriology and Experimental Hematology and Pathology", XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII cycle

2018-act Professor of Hematology PhD "Precision medicine for health and health care" "I" cycle, University of Catania

2022-act Professor of Hematology PhD "Translational Biomedicine" "XXXVIII", "XXXVII", "XXXVI" cycle, University of Catania

2020-Elective Teaching Activity "Indicazioni al trapianto di cellule staminali ematopietiche", University of Catania

2020-act Positive evaluation result provided by the art. 6, paragraphs 7 and 8, of the Law 240/2010 for the purposes of participation in the procedure for the formation of local commissions, Academic Recruitment Field 06/D3 blood diseases, oncology and rheumatology - Academic Discipline MED/15 blood diseases, University of Catania

2020-Highly Transferable Teacher Quantitative Evaluation of Research (VQR) 2015-2019 Orcid 0000-0001-5735-9426

I Level MASTER Teaching, University of Catania

- "Talassemia ed Emoglobinopatie" a.a. 2021-2022

2018-act High-Experience and High Level-Expertise Certificate of Teaching "Staff Development for senior teachers" and "Mentoring Training Project", Area della Formazione Didattica, University of Catania, 18.06.2018

-EUNICE 2021 (European University for Customized Education) (<https://eunice-university.eu/consortium/>) -Translational Collaboration

"Book Chapters" Publications

-Book Chapter in "Current Practice in Medical Science" 2022 Vol. 5 Chapter 12 entitled **"Evaluating the Effect of Anagrelide on Fibroblast Growth Factor Levels"** pag. 113-120, Authors: Rossella Cacciola, Elio Gentilini Cacciola, Emma Cacciola. Editor Dr. Aurora Martinez Romero (Ed) – B P International Publishing.

-Book Chapter in "Current Practice in Medical Science" 2022 Vol. 6 Chapter 13 entitled **"Are TFPI and β -TG indicators of severity in COVID-19?"** pag 161-173, Authors: Rossella Cacciola, Elio Gentilini Cacciola, Veronica Vecchio, Emma Cacciola, Editor Dr. Takashi Ikeno (Ed) – B P International Publishing (2022).

-Book Chapter in "Recent Developments in Medicine and Medical Research" 2021, Vol. 4 Chapter 19 entitled **"Study on effect of anagrelide on platelet factor 4 and vascular endothelial growth factor in patients with essential thrombocythemia"** pag. 162-165, Authors: Rossella R. Cacciola, Ernesto Di Francesco, Rosario Giustolisi, Emma Cacciola. Editor Dr Naseem A. Qureshi (Editor(s)) – Book Publisher International (UK).

-Book Chapter in "New Frontiers in Medicine and Medical Research" 2021, Vol.4 Chapter 18 entitled **"Studies on Antiphospholipid Syndrome"** pag. 149-152, **Authors:** Cacciola Rossella, Gentilini Cacciola Elio, Cacciola Emma. Editors Syed A. A. Rizvi., PhD (Pharmaceutics), PhD (Chemistry), MS, MBA, MSc, BSc. Professor of Pharamveutical Sciences, Hampton University School of Pharmacy (HUSOP) (USA)

-Book chapter in "Manuale di Semeiotica e Metodologia Chirurgica" 2019, Chapter 18 Sezione 18.2 entitled "Iposplenismo e ipersplenismo" Chapter entitled "Milza" Author: Emma Cacciola.

Editors Francesco Basile, Rocco Bellantone, Biondi, Antonio Biondi, Giulio Di Candio, Gianlorenzo Dionigi, Ludovico Docimo, Celestino Pio Lombardi a cura di F.Minni.

-Book chapter in "Manuale di Semeiotica e Metodologia Chirurgica" 2019, Chapter 18 Sezione 18.3 entitled "Malattie di interesse chirurgico" Chapter entitled "Patologie non tumorali" Authors: Francesco Basile, Emma Cacciola, Eva Intagliata, Antonio Giuseppe Biondi.

Editors Francesco Basile, Rocco Bellantone, Biondi, Antonio Biondi, Giulio Di Candio, Gianlorenzo Dionigi, Ludovico Docimo, Celestino Pio Lombardi a cura di F.Minni.

-Book Chapter in "Acta Haematologica" Vol. 97, No 1-2 per i tipi. Karger Basilea 1997 per i tipi. Karger Basilea 1997 Chapter entitled "Adhesion Molecules in Hematology" **Authors:** Emma Cacciola, Rossella Cacciola.

Editors Emma Cacciola, Rossella Cacciola.

-Book Chapter in "Biological role of pluripotent stem cell antigen CD34 in leukemic hematopoiesis" 1994, Chapter entitled "Molecular Biology of Haematopoiesis" – Vol. 3, pp 329-36, **Authors:** E. Caccio P. Guglielmo, E. Cacciola jr., F. Stagno, S. Impera, G. Ferrigno and R. Giustolisi.

Eds. N. G. Abraha R.K. Shadduk – A. S. Levine – F. Takaku – Intercept Ltd PO Bpx 716, Andover Hants SP10 1YG, UK, 1994.

-Book Chapter in "Hematopoietic growth factors, Oncogenes and Cytokines, in Clinical Hematology" 1994, Chapter entitled "Relationship between growth factors, oncogenes and cytokines in the mechanism of aberrant hematopoiesis" pp. 1-21, **Authors:** Giuseppe A. Palumbo, Emma Cacciola, Patrizia Guglielmo, Rosario Giustolisi, Elio Cacciola.

Eds Cacciola E, Deisseroth AB, Giustolisi R, Karger, Basel.

-Book Chapter in "Caratterizzazione istologica ed immunologica dei linfomi non Hodgkin e loro correlazioni con la prognosi" **1988**, Chapter entitled "Indagini citobiologiche nelle emopatie maligne: implicazioni cliniche", pp. 43-52, **Authors:** Elio Cacciola, Rosario Giustolisi, Patrizia Guglielmo, Damiano Murolo, Francesco Di Raimondo, Giuseppe Milone, **Emma Cacciola**, Filippo Buscemi.
Ed. Dennis Quaglino e Girolamo Cretara.

National and International Research Groups

-National Multicenter Observational Perspective Study (No-profit) entitled "Database nazionale sui casi di trombosi con o senza trombocitopenia riscontrati dopo vaccinazione contro SARS-CoV-2" (Siset VAX COVID-19) 31 Marzo 2021 – Promotore: Società Italiana per lo Studio dell'Emostasi e della Trombosi (Siset) – Centro Coordinatore: Prof. Paolo Gresele Sezione di Medicina Vascolare e d'Urgenza Stroke Unit, Dipartimento di Medicina, Azienda Ospedaliera di Perugia

-PRIN study – Bando PRIN 2020 University of Catania entitled "Improvement of the Health-Related Quality of Life and scientific innovation in prognostic approaches in Smoldering Myeloma and Multiple Myeloma patients by "Social Telemedicine", homecare assistance platform based on social advances – Main ERC field: LS - Life Sciences (Principal Investigator: Prof. Angelo Vacca).

-Pia.ce.ri. study 2020/2022 entitled "Microbiome composition and peripheral blood immunome as early biomarkers of response in patients undergoing immunotherapy" (MicroCoSM)" (Coordinatore Principale: Prof. Francesco Di Raimondo), University of Catania.

-Research Group Fondazione Arianna "Studio Giasone (The Jason study) Prevenzione secondaria con sulodexide nei pazienti anziani dopo un tromboembolismo venoso (TEV)" (2018-act).

-Research Group Internazionale F.R.O.M. (Fondazione per la Ricerca Ospedale Maggiore) Ospedale Maggiore Papa Giovanni XXIII di Bergamo - progetto "Tumori Secondari nelle Neoplasie Mieloproliferative (studio MPN-K) (Secondary Cancers in Myeloproliferative Neoplasms (MPN-K study). International and Multicentre study (2018-act).

-Research Group Fondazione Arianna "Misura dei livelli di anticoagulazione nei pazienti in trattamento con i Nuovi Anticoagulanti (NAO), International and Multicentre study "MAS Study ("Measure And See)" Start-(Survey on anTicoagulated pAtients RegisTer-FCSA(Federazione Centri per la Diagnosi della Trombosi e la Sorveglianza delle Terapie Antitrombotiche) (2018-act).

-Research Group Internazionale F.R.O.M. (Fondazione per la Ricerca Ospedale Maggiore) Ospedale Maggiore Papa Giovanni XXIII di Bergamo - progetto PRISM (Preventing Recurrent Ischemic Stroke in Myeloproliferative Neoplasms) "Recurrent ischemic stroke in Ph-negative myeloproliferative neoplasms" (2017).

-Research Group Internazionale F.R.O.M. (Fondazione per la Ricerca Ospedale Maggiore)
Ospedale Maggiore Papa Giovanni XXIII di Bergamo – **International and Multicentre study**
“The benefit/risk profile of pegylated-proline-Interferon-alpha-2b (AOP2014) added to
the best available strategy based on phlebotomies in low-risk patients with
Polycythemia Vera (PV)” (2016-act).

Research Group Internazionale F.R.O.M. (Fondazione per la Ricerca Ospedale Maggiore)
Ospedale Maggiore Papa Giovanni XXIII di Bergamo – **International and Multicentre study**
“AVK/DOACs-MPN Survey” (2015).

-FIR study 2014” (Finanziamento Ricerca d’Ateneo) “Postoperative alteration of
coagulation in advanced laparoscopic surgery: a prospective study” macrosettore European
Research Council (ERC) 01 – Scienze della Vita (LS) (dal 3/07/2014 al 03/07/2016).

-Research Group Fondazione IRCCS “Casa Sollievo della Sofferenza” San Giovanni
Rotondo – Observational and Perspective study “OTTILIA” “Studio Osservazionale
Prospettico sulla prevenzione antitrombotica in donne trombofiliche con abortività
ricorrente” (2016-act).

-Research Group Internazionale F.R.O.M. (Fondazione per la Ricerca Ospedale Maggiore)
Ospedale Maggiore Papa Giovanni XXIII di Bergamo – **International and Multicentre study**
CVT-MNP (Cerebral Vein Thrombosis in Myeloproliferative Neoplasms” (2013).

-Working Party Internazionale GIMEMA (Gruppo Italiano Malattie Ematologiche
dell’Adulto) – International and Multicentre study “Retrospective evaluation of chronic
myeloproliferative neoplasms in patients younger than 40 years” (2010).

-Working Party Internazionale GIMEMA (Gruppo Italiano Malattie Ematologiche
dell’Adulto) – International and Multicentre study “Retrospective evaluation of
hydroxyurea treatment side effects in chronic myeloproliferative neoplasms” (2010).

-Research Group Internazionale Shire United Kingdom - Global Translational
Biopharmaceutical e Biotechnology Company – International and Multicentre study
“EXELS (Evaluation of Xagrid Efficacy and Long-Term Safety)” SPD422-403 “A Phase IIb,
randomised , open label study to compare the safety, efficacy and tolerability of
anagrelide hydrochloride versus hydroxyurea in high-risk essential
thrombocythaemia patients” (2008-2011).

-Working Party Internazionale GIMEMA (Gruppo Italiano Malattie
EMatologiche dell’Adulto) International and Multicentre study - “Valutazione del
potenziale emostatico mediante il test di generazione di trombina sull’outcome di
emorragia e trombosi in pazienti con policitemia vera arruolati nello studio CYTO-PV”
(2008-2011).

-Working Party Internazionale GIMEMA (Gruppo Italiano Malattie Ematologiche
dell’Adulto) – International and Multicentre study “Prospective evaluation of the
predictive role of JAK2V617F allele burden on clinical outcomes in patients with
polycythemia vera” (2008-2009).

-Working Party Internazionale GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) – International and Multicentre study “A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera (PV) – CYTO-PV” (2008-2011).

-Working Party Internazionale GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) – International and Multicentre study “Recurrent thrombosis among patients with polycythemia vera and essential thrombocythemia. Retrospective analysis of the incidence of the events, and of the efficacy and safety of secondary antithrombotic prophylaxis” (2009).

-Research Group Internazionale Shire United Kingdom - Global Translational Biopharmaceutical e Biotechnology Company – European and Multicentre study “EXELS (*Evaluation of Xagrid Efficacy and Long-Term Safety*)” SPD422-401” (2006-2011).

-Working Party Internazionale GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto)- International and Multicentre study “Studio di fase II per la determinazione della dose minima efficace e della tollerabilità di PEG-Interferon alfa-2b nei pazienti con trombocitemia essenziale” (2001).

-International and Multicentre “ECLAP study” (European Collaboration on Low Dose Aspirin in Polycythaemia Vera) (1997).

Multidisciplinary Research Groups, University of Catania

2021-act **“Papilloma Virus Pathology”**

2020-act **“Diagnosis and therapy of the Fabry’s Disease and the Organ Transplant”**

2020-act **“Molecular and Preclinic and Translational Imaging (IMPRonTE)”**

2018-act **“Center Excellence for the Acceleration of HarmReduction (CoEHAR)”**

2016-act **“Diagnosis and Therapy of the Rare Diseases”**

2016-act **“Mini Invasive Surgical Techniques”**

2020-act Pharmaceutical Training, Certificate of Graduation GOOD CLINICAL PRACTICE, Trainer: Stefano Lagravinese

Invited Reviewer for international Scientific Journals:

2005-act Reviewer for the journal “Drugs”

2016-act Reviewer for the journal “Thrombosis Research”

2017-act Reviewer for the journal “Leukemia Research”

2022-act Reviewer for the journal “Vaccines”

2022-act Reviewer for the journal “Biomedicines”

2022-act Reviewer for the journal "Bioengineering"

2022-act Reviewer for the journal "Diagnostics"

2022-act Reviewer for the journal "Journal of Cardiovascular Development and Disease"

2021-act Guest Editor for the journal "**Journal of Clinical Medicine**", Special Issue
"Thrombocythemia: Current Status, Challenges and Future Directions"

Society Membership:

1989-act **Italian Society of Experimental Biology**

1991-act **New York Academy of Sciences**

1991-act **Italian Society of Hematology Membership n. 41**

1996-act **American Society of Hematology (ASH) Membership n. 0000127506**

2000-act **International Society on Thrombosis and Haemostasis (ISTH) Membership n. 4223**

2013-act **Federazione Centri per la Diagnosi e la Sorveglianza delle Terapie Antitrombotiche (F.C.S.A.)**

2020-act **European Hematology Association (EHA) Membership n. 079364**

Publications

Prof. Emma Cacciola is author of over 300 peer reviewed papers in various international journals and meetings.

Cacciola 1/10/2023

Emma Cacciola